Effectiveness of Antenatal Anti-D Prophylaxis Figure 1. Elicitation scales. Elicitation scales for quantifying additive biases on a relative risk scale and for quantifying proportional biases as proportional change to (log) relative risk. doi:10.1371/journal.pone.0030711.g001 Table 1. Summary of characteristics of studies comparing RAADP to control, with reported odds ratios for sensitisation. Study Bowman (1) [6] Bowman (2) [7] Bowman (3) [8] Hermann [9] Huchet [10] Lee [11] MacKenzie [12] Mayne [13] Tovey [14] Trolle [15] Population Non-sensitised Rh2 women delivered of Rh+ babies in a Canadian province Non-sensitised Rh2 women delivered of Rh+ babies in a Canadian province Non-sensitised Rh2 women delivered of Rh+ babies in a Canadian province Non-sensitised Rh2 women delivered of Rh+ babies at a Swedish hospital Rh2 primiparae delivered of Rh+ babies in 23 Parisian maternity units Rh2 primigravidae delivered of Rh+ babies in several UK obstetric units Non-sensitised Rh2 primiparae delivered of Rh+ babies in two UK counties Rh2 primigravidae delivered of Rh+ babies in Derbyshire, UK Rh2 primigravidae delivered of Rh+ babies in Yorkshire, UK Non-sensitised Rh2 women delivered of Rh+ babies at a Danish hospital doi:10.1371/journal.pone.0030711.t001 Intervention Two doses of 1500 IU anti-D Ig, given at 28 and 34 weeks’ gestation, in addition to control care Control 1500 IU anti-D Ig given within 72 hours after delivery of a Rh+ baby or abortion One dose of 1500 IU anti-D 1500 IU anti-D Ig given Ig, given at 28 weeks’ gestation, within 72 hours after in addition to control care delivery of a Rh+ baby or abortion One dose of 1500 IU anti-D 1500 IU anti-D Ig given Ig, given at 28 weeks’ gestation, within 72 hours after in addition to control care delivery of a Rh+ baby or abortion One dose of 1250 IU anti-D Ig, 1250 IU anti-D Ig given given at 32–34 weeks’ gestation, within 72 hours after in addition to control care delivery of a Rh+ baby Two doses of 500 IU anti-D Ig, given at 28 and 34 weeks’ gestation, in addition to control care Two doses of 250 IU anti-D Ig, given at 28 and 34 weeks’ gestation, in addition to control care Two doses of 500 IU anti-D Ig, given at 28 and 34 weeks’ gestation, in addition to control care Two doses of 500 IU anti-D Ig, given at 28 and 34 weeks’ gestation, in addition to control care Two doses of 500 IU anti-D Ig, given at 28 and 34 weeks’ gestation, in addition to control care One dose of 1500 IU anti-D Ig, given at 28 weeks’ gestation, in addition to control care 500 IU anti-D Ig given after delivery of a Rh+ baby, repeated if necessary Anti-D Ig given after delivery and after potentially sensitising events ‘‘in the usual way’’ (UK, 1992), doses not stated ‘‘Standard’’ anti-D prophylaxis given after delivery and after potentially sensitising events (UK, 1990–1996), doses not stated 500 IU anti-D Ig given after delivery of a Rh+ baby, or a higher dose if the Kleihauer count was abnormal 1000 IU anti-D Ig given after delivery of a Rh+ baby Outcome Sensitisation during pregnancy or within 3 days after delivery Sensitisation at delivery Sensitisation at delivery Sensitisation at 8 months postpartum OR (95% CI) 0.02 (0.001, 0.33) 0.34 (0.18, 0.65) 0.18 (0.12, 0.28) 0.24 (0.05, 1.10) Sensitisation at 2–12 0.14 (0.02, 1.14) months postpartum Sensitisation at 6 months postpartum 0.56 (0.14, 2.24) Sensitisation during second pregnancy 0.44 (0.22, 0.86) Sensitisation in a subsequent pregnancy Sensitisation at 10 months postpartum 0.25 (0.08, 0.74) 0.16 (0.04, 0.67) 0.08 (0.005, 1.49) No information provided Sensitisation on control care; study during second or setting was UK, 1988–1990 subsequent pregnancy PLoS ONE | www.plosone.org 4 February 2012 | Volume 7 | Issue 2 | e30711